GRIK1
Glutamate receptor ionotropic, kainate 1
As of the edition of 20 October 2026, GRIK1 (glutamate receptor ionotropic, kainate 1, UniProt P39086) has 4 drugs tested at it and 7 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P39086
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 11
- Disease areas
- Nervous system; Mental health; Nutrition and metabolism; Chemically induced; Hormones; Heart and blood vessels; Inherited and neonatal; Immune system
- Registered trials of its drugs
- 228
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Topiramate | Marketed | Phase 4 | none listed |
| Selurampanel | Stopped | Phase 2 | none listed |
| Tezampanel anhydrous | Active | Phase 2 | none listed |
| Dasolampanel | Went quiet | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 5 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Johnson & Johnson | Route B |
| Novartis | Route A |
The other 5 companies at GRIK1
In the product7 companies in all; 5 are not named here, and no score is.
See the 7 companies at GRIK1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.